Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer

Preclinical data support a role for the IL-6/JAK2/STAT3 signaling pathway in breast cancer. Ruxolitinib is an orally bioavailable receptor tyrosine inhibitor targeting JAK1 and JAK2. We evaluated the safety and efficacy of ruxolitinib in patients with metastatic breast cancer. This was a non-randomi...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:NPJ Breast Cancer
Egile Nagusiak: Stover, Daniel G., Gil Del Alcazar, Carlos R., Brock, Jane, Guo, Hao, Overmoyer, Beth, Balko, Justin, Xu, Qiong, Bardia, Aditya, Tolaney, Sara M., Gelman, Rebecca, Lloyd, Maxwell, Wang, Yu, Xu, Yaomin, Michor, Franziska, Wang, Vivian, Winer, Eric P., Polyak, Kornelia, Lin, Nancy U.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group UK 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5935675/
https://ncbi.nlm.nih.gov/pubmed/29761158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-018-0060-z
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak